keyword
MENU ▼
Read by QxMD icon Read
search

capecitabine

keyword
https://www.readbyqxmd.com/read/29159517/correction-to-phase-i-dose-finding-study-of-eribulin-and-capecitabine-for-metastatic-breast-cancer-jbcrg-18-cape-study
#1
Masaya Hattori, Hiroshi Ishiguro, Norikazu Masuda, Akiyo Yoshimura, Shoichiro Ohtani, Hiroyuki Yasojima, Satoshi Morita, Shinji Ohno, Hiroji Iwata
The article "Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study", written by Masaya Hattori, Hiroshi Ishiguro, Norikazu Masuda, Akiyo Yoshimura, Shoichiro Ohtani, Hiroyuki Yasojima, Satoshi Morita, Shinji Ohno, and Hiroji Iwata, was originally published electronically on the publisher's Internet portal (currently SpringerLink) on 31 August 2017 without open access. With the author(s)' decision to opt for Open Choice the copyright of the article changed on [9 November 2017] to...
November 20, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/29158782/a-phase-ii-trial-of-preoperative-concurrent-chemotherapy-and-dose-escalated-intensity-modulated-radiotherapy-imrt-for-locally-advanced-rectal-cancer
#2
Jeremy Tey, Cheng Nang Leong, Wai Kit Cheong, Tay Guan Sze, Wei Peng Yong, Ivan Weng Keong Tham, Khai Mun Lee
Objectives: To determine the pathological response rates and toxicity and in patients with locally advanced rectal cancer treated with concurrent capecitabine and dose escalated intensity modulated radiotherapy (IMRT) Methods: Patients with stage II or III adenocarcinoma of the rectum were treated with preoperative concurrent capecitabine and IMRT. Dose of capecitabine was 825mg/m(2), 5 days a week for 5 weeks. IMRT was used to deliver a dose of 45Gy in 25 fractions (1.8Gy per fraction daily, 5 days a week over 5 weeks) to the regional lymphatics and areas at risk of harbouring microscopic disease...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/29158693/adenocarcinoma-arising-from-a-gastric-duplication-cyst-a-case-report-and-literature-review
#3
Maheeba Abdulla Mohamed Abdulla, Mahmood Al Saeed, Safa Ameer Alshaikh, Umesh J Nabar
Introduction: Alimentary tract cystic duplication is a rare congenital anomaly predominantly affecting females, and diagnosed mostly in the early years of life. Case report: We present here a case of a 51-year-old man presenting with a 2-day history of melena. Gastroscopy showed fresh blood, as well as a mass lesion and cavity at the fundus. Biopsies of the mass edge reported the occurrence of moderately differentiated adenocarcinoma and mild chronic gastritis. Computed tomography imaging showed a 5...
2017: International Medical Case Reports Journal
https://www.readbyqxmd.com/read/29158365/phase-ii-trial-using-a-combination-of-oxaliplatin-capecitabine-and-celecoxib-with-concurrent-radiation-for-newly-diagnosed-resectable-rectal-cancer
#4
Emilio P Araujo-Mino, Yehuda Z Patt, Cristina Murray-Krezan, Joshua A Hanson, Pranshu Bansal, Ben J Liem, Ashwani Rajput, M Houman Fekrazad, Glenory Heywood, Fa Chyi Lee
LESSONS LEARNED: Colorectal cancers exhibit a high level of cyclooxygenase-2 (COX-2) expression with strong preclinical rationale for improved clinical outcomes with COX-2 inhibition. Celecoxib is a COX-2 inhibitor and we have shown that it can be safely combined with capecitabine and oxaliplatin as part of neoadjuvant treatment with radiation therapy (RT) in rectal cancer.There was a significant improvement in skin toxicity with this combination as compared with historical data. Considering the field has moved on to single-agent capecitabine, we believe future trials with capecitabine and celecoxib hold potential...
November 20, 2017: Oncologist
https://www.readbyqxmd.com/read/29156864/evaluation-of-lipid-profiles-in-patients-treated-with-capecitabine
#5
Nursel Sürmelioğlu, Semra Paydaş, Yusuf Karataş, Gülşah Seydaoğlu
Background/aim: Capecitabine is a prodrug of 5-fluorouracil and has shown significant antitumor activity. The main adverse effects are hand-foot syndrome, diarrhea, and dermatitis. In recent years, hypertriglyceridemia has been reported in patients treated with capecitabine. Dyslipidemia is a rare but important side effect of capecitabine. The aim of this study is to examine the changes in lipid levels during capecitabine treatment and to raise awareness of pharmacovigilance. Materials and methods: In this retrospective study, it was aimed to analyze lipid metabolism after capecitabine treatment and is intended to contribute to the formation of a pharmacoepidemiological database...
August 23, 2017: Turkish Journal of Medical Sciences
https://www.readbyqxmd.com/read/29156843/clinical-efficacy-of-neoadjuvant-chemotherapy-regimens-fleeox-vs-xelox-in-patients-with-initially-unresectable-advanced-gastric-cancer-a-propensity-score-analysis
#6
Yang Li, Jun Chen, Qi He, Xiang Ji, Xulin Wang, Chaogang Fan, Guoli Li
Purpose: This study was designed to assess the effectiveness of FLEEOX (5-Fu, leucovorin, etoposide, oxaliplatin, and epirubicin) compared with XELOX (capecitabine and oxaliplatin) as neoadjuvant chemotherapy (NAC) for initially unresectable advanced gastric cancer (AGC). Methods: This study reviewed patients who underwent FLEEOX or XELOX for initially unresectable AGC. To reduce the bias in patient selection, we conducted propensity score match (PSM) with 1:1 ratio...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29155514/the-prognostic-effect-of-neoadjuvant-chemoradiotherapy-on-the-change-of-pd-l1-expression-in-patients-with-locally-advanced-rectal-adenocarcinoma
#7
Igor Richter, Tomas Jirasek, Josef Dvorak, Eva Cermakova, Petra Rehakova, Jiri Bartos
PURPOSE: To evaluate the prognostic effect of neoadjuvant chemoradiotherapy on the change of programmed death ligand 1 (PD-L1) expression in patients with locally advanced rectal adenocarcinoma, by comparing PD-L1 expression in pretreatment biopsies and PD-L1 expression in pathological specimens after neoadjuvant chemoradiotherapy. METHODS: A total of 25 patients with rectal adenocarcinoma were evaluated. Patients were treated by neoadjuvant chemoradiotherapy (radiotherapy:44Gy normofraxionation; chemotherapy: capecitabine 825 mg/m(2) in two daily doses)...
July 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29153866/a-phase-i-trial-of-the-pi3k-inhibitor-buparlisib-combined-with-capecitabine-in-patients-with-metastatic-breast-cancer
#8
Autumn J McRee, Paul K Marcom, Dominic T Moore, William C Zamboni, Zachary A Kornblum, Zhiyuan Hu, Rachel Phipps, Carey K Anders, Katherine Reeder-Hayes, Lisa A Carey, Karen E Weck, Charles M Perou, E Claire Dees
BACKGROUND: Buparlisib is an oral pan-class I phosphotidyinositol-3-kinase (PI3K) inhibitor. The present phase I study evaluated the safety, pharmacokinetics, and efficacy of buparlisib with capecitabine in patients with metastatic breast cancer. PATIENTS AND METHODS: Patients received buparlisib once daily (range, 50 to 100 mg) for 3 weeks with capecitabine twice daily (range, 1000 to 1250 mg/m(2)) for 2 weeks with a 1-week break. Dose escalation used a traditional "3 + 3" design with standard definitions of dose-limiting toxicity (DLT) and maximum tolerated dose...
October 28, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29152729/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-dihydropyrimidine-dehydrogenase-genotype-and-fluoropyrimidine-dosing-2017-update
#9
Ursula Amstutz, Linda M Henricks, Steven M Offer, Julia Barbarino, Jan H M Schellens, Jesse J Swen, Teri E Klein, Howard L McLeod, Kelly E Caudle, Robert B Diasio, Matthias Schwab
The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost-effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC(®) ) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx...
November 20, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29145260/reversible-severe-fatty-liver-induced-by-capecitabine-a-case-report
#10
Yiyan Jiang, Qiancheng He, Suxia Li, Chang Shi, Xiaolei Yang
RATIONALE: Capecitabine (CAP) is a chemotherapeutic agent used to treat breast and gastrointestinal cancers. The most common adverse reactions of CAP primarily included gastrointestinal and dermatological effects. Whereas, the CAP-induced fatty liver had never been reported. PATIENT CONCERNS: In this study, a-69-year old female presented a history of hypertension with regulated blood pressure, whereas diabetes mellitus, hyperlipidemia, and hepatitis were excluded...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29143893/the-role-of-systemic-therapy-in-resectable-gastric-and-gastro-oesophageal-junction-cancer
#11
REVIEW
Elizabeth Cartwright, David Cunningham
Approximately 20% of patients with cancer of the stomach or gastro-oesophageal junction (GOJ) present with resectable disease. Long-term outcome after surgery alone in these patients is poor, and a combined treatment approach is the standard of care. The two approaches to managing patients with cancer of the GOJ are perioperative chemotherapy or preoperative chemoradiotherapy. Based upon the most recent evidence, patients treated with a perioperative approach and deemed suitable for a triplet regimen should be considered for pre- and post-operative FLOT (5-fluorouracil [5-FU], leucovorin, oxaliplatin and docetaxel) and those suitable for a doublet regimen should be considered for a fluoropyrimidine/platinum combination such as capecitabine and oxaliplatin...
November 16, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29142750/evaluation-of-epidermal-growth-factor-receptor-serum-levels-and-their-association-with-clinicopathological-characteristics-in-patients-with-colorectal-cancer
#12
Mehmet Karabulut, Cigdem Usul Afsar, Halil Alıs, Ebru Oran, Senem Karabulut, Cevher Akarsu, Nuri Alper Sahbaz, Alpen Yahya Gümüsoglu, Elif Bilgin, Nuri Faruk Aykan
Colorectal cancer (CRC) is a major public health concern and one of the leading causes of cancer-related mortality worldwide. The aim of the present study was to determine the serum epidermal growth factor receptor (sEGFR) levels in healthy volunteers and patients with CRC, to determine the association between tumor marker levels and clinicopathological findings, and investigate its prognostic value. A total of 140 patients with CRC were enrolled in the present study. Pre-treatment sEGFR levels were determined using ELISA...
November 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29130233/-clinical-features-and-prognosis-analysis-of-21-gastric-cancer-patients-with-pathological-complete-response-after-neoadjuvant-chemotherapy
#13
Liangqun Peng, Wei Yang, Zhandong Zhang, Hongxing Liu, Yawei Hua
OBJECTIVE: To evaluate the clinical features and prognosis of gastric cancer patients with pathological complete response (pCR) after neoadjuvant chemotherapy (NAC). METHODS: Clinical data of 159 gastric cancer patients who received NAC followed by surgical resection between January 2012 and December 2014 at the Affiliated Tumor Hospital of Zhengzhou University were collected and clinical features of those with pCR were analyzed retrospectively. Kaplan-Meier method was used to estimate 3-year overall survival (OS) rate and recurrence-free survival (RFS) rate...
October 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/29129089/systemic-therapy-for-esophageal-cancer-chemotherapy
#14
Geoffrey Y Ku
As one-half of patients with esophagogastric cancer (EGC) present with metastatic disease and the majority of patients with locally advanced disease will eventually develop metastatic disease despite multimodality therapy, most patients will receive palliative chemotherapy at some point. The reference first-line regimen consists of a fluoropyrimidine/platinum combination, which is the standard in East Asia, where this disease is endemic. Options include infusional 5-fluorouracil (5-FU), capecitabine, S-1 and other oral 5-FU pro-drugs and cisplatin or oxaliplatin...
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29127435/intensified-preoperative-chemoradiation-by-adding-oxaliplatin-in-locally-advanced-primary-operable-ct3nxm0-rectal-cancer-impact-on-long-term-outcome-results-of-the-phase%C3%A2-ii-tako-05-abcsg-r%C3%A2-02-trial
#15
P Kogler, A F DeVries, W Eisterer, J Thaler, L Sölkner, D Öfner
PURPOSE: The major goals of preoperative treatment for locally advanced rectal cancers (LARCs) are improvement of local tumor control, tumor downsizing, and downstaging. Modifications with respect to standardized chemoradiation protocol, e. g., integrating oxaliplatin, are realized with the aim of improving primary tumor response and patient outcome. PATIENTS AND METHODS: In this phase II multicenter study, patients with LARC of the mid- or lower rectum, cT3cNxcM0 as staged by MRI, were included and treated preoperatively with a combination of capecitabine and oxaliplatin following a standardized protocol during radiation...
November 10, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29121830/acute-reversible-toxic-encephalopathy-during-capecitabine-and-oxaliplatin-treatment
#16
João Godinho, Mafalda Casa-Nova, Teresa Mesquita, Maria João Baptista, Francisco Araújo, José Vale, José Luís Passos Coelho
Introduction Capecitabine is a fluoropyrimidine commonly used in the treatment of colorectal cancer which may cause central nervous system toxicity, namely cerebellar dysfunction. Case report We describe a 77-year-old man undergoing adjuvant treatment of colon cancer with capecitabine and oxaliplatin who presented with acute cerebellar ataxia and encephalopathy that progressed to coma. Diagnosis of toxic encephalopathy was made after the exclusion of alternative causes of neurological dysfunction and complete resolution of clinical findings with permanent discontinuation of chemotherapy...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29117755/contribution-of-oxidative-stress-in-acute-intestinal-mucositis-induced-by-5-fluorouracil-5-fu-and-its-pro-drug-capecitabine-in-rats
#17
Kaïs Rtibi, Slimen Selmi, Dhekra Grami, Mohamed Amri, Hichem Sebai, Lamjed Marzouki
This study was designed to examine the contribution of oxidative stress in gastrointestinal disorders after an intraperitoneal administration of 5-FU (100mg/kg b.w.) and capecitabine oral administration (500mg/kg b.w.). The animals were divided into three groups: Group A (NaCl, 10ml/kg b.w.) considered as control group, group B was intoxicated by 5-FU and the group of animals (group C) treated with capecitabine (CAP). To evaluate the secretory and enteropooling effects, we were used as a hypersecretion agent (MgSO4, 1ml/100g b...
November 8, 2017: Toxicology Mechanisms and Methods
https://www.readbyqxmd.com/read/29117285/topical-timolol-for-paronychia-and-pseudopyogenic-granuloma-in-patients-treated-with-epidermal-growth-factor-receptor-inhibitors-and-capecitabine
#18
Xavier Cubiró, Sergi Planas-Ciudad, Mª Pilar Garcia-Muret, Lluís Puig
No abstract text is available yet for this article.
November 8, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/29113420/evaluating-the-benefits-and-adverse-effects-of-an-enthracycline-taxane-capecitabine-combined-regimen-in-patients-with-early-breast-cancer
#19
REVIEW
Jiantang Zhang, Fangmeng Fu, Yuxiang Lin, Yazhen Chen, Minjun Lu, Minyan Chen, Peidong Yang, Meng Huang, Chuan Wang
Capecitabine in addition to anthracycline-taxane based regimens for patients with early breast cancer (EBC) has been reported in previous clinical trials, but the reported efficacy of this regimen remained inconsistent. In order to clarify the survival benefit of this regimen, a meta-analysis was performed. The systematic literature search was conducted in PubMed, the Cochrane library and Google scholar. The hazard ratios (HRs) were used to evaluate the efficacy and adverse events. The result indicated that capecitabine combine with an anthracycline-taxane based regimen would significantly improve DFS (HR = 0...
October 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/29113401/optimal-adjuvant-chemotherapy-for-resected-pancreatic-adenocarcinoma-a-systematic-review-and-network-meta-analysis
#20
Jian-Bo Xu, Bin Jiang, Ya Chen, Fu-Zhen Qi, Jian-Huai Zhang, Hang Yuan
Adjuvant chemotherapy improves survival in patients with resected pancreatic cancer but the optimal regimen remains unclear. We aim to compare all possible adjuvant chemotherapy in terms of overall survival and toxic effects. Pubmed, Trial registries and Cochrane library databases for randomized controlled trials were searched until November 2016. Thirteen trials were included for network analysis and the hazard ratios (HRs) for survival and odds ratios for toxic effects were assessed via Aggregate Data Drug Information System software...
October 6, 2017: Oncotarget
keyword
keyword
20530
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"